GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: TRIUMPH stopped being a problem at week 45 — 27 comments in the full submission. View in context.
476
c/trialwatch·submitted 1 year ago by u/rohan_cardoso

small win: TRIUMPH stopped being a problem at week 45

Paperbranch of 6 comments

Week 32 update. 43kg down from the start, reflux basically gone since about week 84. Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with reflux. The part that surprised me is how much of this is admin. Ordering,…

Read the full submission and all 27 comments →

This branch

6 comments, started 1 year ago
u/britta_boateng25 points·1 year ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/foam_head_fred12 points·1 year ago

number-needed-to-treat is the house dialect

Disagree on that part. 98.4% and 98.3% on the same vial is normal.

replysharereportpermalink
u/rulebook_rachaelmod · c/meta8 points·1 year ago

Small correction: the trial was 4 weeks, not 31. Does not change your point but people will quote it.

replysharereportpermalink
[removed]4 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/milan_villalobos1 point·1 year ago

That is net peptide content, not purity. Different number, different meaning.

replysharereportpermalink
u/rina_bergstrom4 points·1 year ago

dropout handling matters, especially on GI-heavy populations

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →